Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis

Zhu Zhong Shan; Yan Wen Hui; Li Xiao Bing; Yang Zhou; Bai Peng

Article Contents

Article Navigation > Journal of Kunming Medical University > 2018 > 39(08): 47-50

Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis[J]. Journal of Kunming Medical University, 2018, 39(08): 47-50.

Citation:

Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis[J]. Journal of Kunming Medical University, 2018, 39(08): 47-50.

Citation:

PDF( 270 KB)

Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis

Funds:

基金：湖南省卫计委科研计划基金资助项目 (B2013087);

Received Date: 2018-06-13

Abstract

Abstract

Objective To investigate the relationship between the driver genes mutation and the survival in patients with pulmonary adenocarcinoma brain metastasis. Methods We enrolled 200 patients with pulmonary adenocarcinoma brain metastasis confirmed histologically from Jan 2013 to Dec 2015, and tested EGFR, KRAS, ALK, Her-2 gene mutation, analyzed the relationship between EGFR gene mutation and clinicopathological data and prognosis of the patients.Results The mutation rates of EGFR, KRAS, ALK and Her-2 gene mutation were 48.5%, 5.5%, 6.5%, 3.5%, respectively. Compared with EGFR gene mutation patients, the sex, age, BMI, differentiation were significant different (P<0.05) , however, the smoking was not significant different (P>0.05) . Patients with EGFR gene mutation who received targeted therapy survived longer than who did not receive targeted therapy, (28.0 ±4.5) months vs (11.2 ±1.4) months. By Log Rank (Mantel-Cox) , the median survival time between the two groups was statistically significant (P<0.05) .Conclusions The mutation rate of EGFR gene mutation was high in patients with pulmonary adenocarcinoma brain metastasis, and the patients will survivel longer by targeted therapy.
- Pulmonary adenocarcinoma,
- Brain metastasis,
- Targeted therapy,
- Driver gene

FullText(HTML)

References(21)

References

[1]	[1]FERLAY J S I.Incidence/Mortality Data.GLOBOCAN2012 v1.0, Cancer Incidence and Mortality Worldwide:IARC Cancer Base No.11[Internet].International Agency for Research on Cancer, Lyon, France, 2013.Available from URL:http://globocan.iarc.fr.
[2]	[2]GLOBOCAN 2012:Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012[EB/OL].http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx, 2013-12-12.
[3]陈万青, 张思维, 曾红梅, 等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤, 2014, 23 (1) :1-10.
[4]石岳泉, 杨向红.非小细胞肺癌的驱动基因及其临床意义[J].中国肺癌杂志, 2014, 17 (6) :481-486.
[5]	[5]SHI Y, AU J S, THONGPRASERT S, et al.A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) [J].J Thorac Oncol, 2014, 9 (2) :154-162.
[6]	[6]LI H, PAN Y, LI Y, et al.Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose[J].Lung Cancer, 2013, 79 (1) :8-13.
[7]	[7]KIM H R, KIM D J, KANG D R, et al.Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer[J].J Clin Oncol, 2013, 31 (6) :731-737.
[8]	[8]LINDEMAN N I, CAGLE P T, BEASLEY M B, et al.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular pathology[J].J Thorac Oncol, 2013, 8 (7) :823-859.
[9]	[9]ROSELL R, CARCERENY E, GERVAIS R, et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation positive non small cell lung cancer (EURTAC) :a multicentre, open label, randomised phase3 trial[J].Lancet Oncol, 2012, 13 (3) :239-246.
[10]张娜, 王文彤, 陶遵威.非小细胞肺癌分子靶向治疗的最新研究进展[J].天津药学, 2015, 27 (1) :44-46.
[11]	[11]COSTA C, MOLINA M A, DROZDOWSKYJ A, et al.The impact of EGFR T790M mutations and BIM m RNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial[J].Clin Cancer Res, 2014, 20 (7) :2001-2010.
[12]	[12]GAZDAR A F.EGFR mutations in lung cancer:Different frequencies for different folks[J].J Thorac Oncol, 2014, 9 (2) :139-140.
[13]	[13]NAKAMURA R, INAGE Y, TOBITA R, et al.Epidermal growth factor receptor mutations:effect on volume doubling time of non-small-cell lung cancer patients[J].J Thorac Oncol, 2014, 29 (9) :1294-1304.
[14]	[14]XU Z, HANG J, HU J, et al.Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells[J].J Buon, 2014, 19 (2) :466-473.
[15]赵建国, 徐农.非小细胞肺癌的分子分型[J].实用肿瘤杂志, 2014, 29 (5) :399-403.
[16]	[16]LI Y, LI Y, YANG T, et al.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS genemutations in 208 Chinese patients with nonsmall cell lung cancer[J].Plos One, 2013, 8 (1) :e52093.
[17]	[17]KRIS M G, JOHNSON B E, BERRY L D, et al.Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J].Jama, 2014, 311 (19) :1998-2006.
[18]王辉, 王英浩, 陈晓英.放射治疗联合厄洛替尼对肺腺癌脑转移的疗效分析[J].中国医药导刊, 2016, 18 (2) :137-139.
[19]张帆.EGFR-TKIs联合全脑放疗与全脑放疗治疗肺腺癌脑转移疗效分析[J].中国医学工程, 2014, 22 (12) :71-72.
[20]陈雪琴, 杨邵瑜, 黄杰, 等.肺腺癌患者驱动基因表达及生存分析[J].实用肿瘤杂志, 2016, 31 (3) :246-269.
[21]周荻, 徐欣, 谢华英, 等.全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移疗效分析[J].上海交通大学学报 (医学版) , 2013, 33 (4) :480-484.

Relative Articles(20)

Relative Articles

[1]	Shengqiang YANG, Ping WANG. Effect of Hsp90 Inhibitor Ganetespib Combined with Pemetrexed on Lung Adenocarcinoma Cells. Journal of Kunming Medical University, 2024, 45(7): 30-41. doi: 10.12259/j.issn.2095-610X.S20240705
[2]	Wangxun SHEN, Yinyu YANG, Canwei LI, Jinrong YANG, Sijing WU, Huajun ZHAO, Xiaoyu TUO. Expression and Clinical Significance of ROR1 in Different Histologic Types of Invasive Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20240509
[3]	Hongxiu YANG, Zhongshan ZHU. Effect of HPRT1 Gene Expression on Overall Survival of Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(8): 17-23. doi: 10.12259/j.issn.2095-610X.S20240803
[4]	Shiqi MA, Yi DING, Min LI, Mengci WANG, Siyu ZHANG, Shumei FENG. LINC00341 Inhibits the Proliferation of Lung Adenocarcinoma Cells Through the MAPK Pathway. Journal of Kunming Medical University, 2023, 44(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20230403
[5]	Fei SONG, Jiayin CHE, Ming HUANG, Dan XU, Hongyang LI, Dingkun LI, Yingying XIANG. The Role of Radioactive Iodine-125 Particles in EMT and Clinical Treatment of Lung Adenocarcinoma. Journal of Kunming Medical University, 2023, 44(1): 140-143. doi: 10.12259/j.issn.2095-610X.S20230101
[6]	Chenxi LI, Zhuocen ZHA, Na LI, Lin LUO, Yang YANG, Wenlin CHEN. Selection of Intensive Adjuvant Therapy for Triple-positive Breast Cancer. Journal of Kunming Medical University, 2023, 44(10): 180-188. doi: 10.12259/j.issn.2095-610X.S20231020
[7]	Bangqing LIU, Jianfeng LI, Xiaohui LIU, Jinnan ZHANG, Jinping LIANG. MiR-196b Promotes Proliferation and Migration of Lung Adenocarcinoma by Targeting ERG. Journal of Kunming Medical University, 2023, 44(10): 83-91. doi: 10.12259/j.issn.2095-610X.S20231023
[8]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927
[9]	Qiao LUO, Hong SHI, Shaobo WANG. Role of α7-nicotinic Acetylcholine Receptor in Occurrence，Development and Therapy of Lung Cancer. Journal of Kunming Medical University, 2022, 43(2): 145-149. doi: 10.12259/j.issn.2095-610X.S20220226
[10]	Zhongshan ZHU, Zhou YANG, Chengchuan JIANG, Xiaobing LI, Dou REN, Cheng HUANG, Weiwei ZHANG, Xiangjun LI, Shunli ZHAO. An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, 2022, 43(9): 70-76. doi: 10.12259/j.issn.2095-610X.S20220912
[11]	Huajun ZHAO, Guoqing PAN, Ying TANG, Zhiyuan WANG, Xiaowei ZHAO, Xiaoyu TUO. Expressions of ROR1 in Lung Adenocarcinoma and Its Relationship with Spread Through Air Apace. Journal of Kunming Medical University, 2022, 43(11): 22-29. doi: 10.12259/j.issn.2095-610X.S20221128
[12]	Maofang WU, Yongchun ZHOU, Jingjing CAI, Xin MO, Yinwei LI, Jiahui MAO. EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province. Journal of Kunming Medical University, 2022, 43(2): 60-66. doi: 10.12259/j.issn.2095-610X.S20220215
[13]	Hong-min DUAN, Nan CHEN, Yong-yan YANG, Yun-xia LI, Jin-xiang FENG, Hang LI, Xiu-wen HUANG, Dong-jin LV, Ming ZHANG, Yu-tao ZHAO. Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549. Journal of Kunming Medical University, 2021, 42(8): 40-46. doi: 10.12259/j.issn.2095-610X.S20210808
[14]	Yan-fen MA, Jian HU, Ning ZHANG, Qian WU, Xiao-qin WANG. Changes and Abnormal Patterns of Coagulation Indicators in Patients with Lung Adenocarcinoma and Tuberculosis Pleural Effusion. Journal of Kunming Medical University, 2021, 42(10): 145-150. doi: 10.12259/j.issn.2095-610X.S20211021
[15]	Wu Qi Yan , Bian Ge Yuan , Cheng Hui Jun, Li Jiao Xia , Wang Shu Ting , Huang Zhao Lue . . Journal of Kunming Medical University, 2020, 41(09): 32-37.
[16]	Zhang Zhi Xian , Gu Hou , Lin 劼, Lei Xue Fen , Jiang Li Feng , Li Nan , Lu Xin Yan , Li Ting Ting . . Journal of Kunming Medical University, 2018, 39(12): 65-68.
[17]	Huang Sai Jun , Ge Fei , Chen Wen Lin , Li Yun Xi , Tan Lin Yan , Wang Xi . . Journal of Kunming Medical University, 2018, 39(12): 125-129.
[18]	Zhou Jiu Peng . . Journal of Kunming Medical University,
[19]	Wang Hua . . Journal of Kunming Medical University,
[20]	Chen Xian Yu . . Journal of Kunming Medical University,